Ernest Mario just Picked up 16,500 shares of Tonix Pharmaceuticals Holding Corp. (TNXP), be careful if you are short!; Birchcliff Energy Ltd. (TSE:BIR) Covered By 7 Bullish Analysts Last Week

June 27, 2018 - By Danny Collins

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Logo

Among 8 analysts covering Birchcliff Energy Ltd. (TSE:BIR), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Birchcliff Energy Ltd. had 31 analyst reports since July 21, 2015 according to SRatingsIntel. Scotia Capital maintained the shares of BIR in report on Monday, August 22 with “Focus Stock” rating. The firm earned “” rating on Monday, June 6 by Raymond James. The firm earned “Outperform” rating on Friday, February 12 by BMO Capital Markets. RBC Capital Markets upgraded the shares of BIR in report on Thursday, February 11 to “Outperform” rating. On Thursday, March 16 the stock rating was maintained by TD Securities with “Buy”. Scotia Capital maintained it with “Focus Stock” rating and $12 target in Friday, August 12 report. The stock of Birchcliff Energy Ltd. (TSE:BIR) has “Focus Stock” rating given on Thursday, March 16 by Scotia Capital. The firm earned “Outperform” rating on Tuesday, March 21 by Raymond James. The stock of Birchcliff Energy Ltd. (TSE:BIR) earned “Sector Perform” rating by RBC Capital Markets on Friday, January 22. See Birchcliff Energy Ltd. (TSE:BIR) latest ratings:

The stock increased 2.57% or $0.12 during the last trading session, reaching $4.79. About 1.63M shares traded. Birchcliff Energy Ltd. (TSE:BIR) has 0.00% since June 27, 2017 and is . It has underperformed by 12.57% the S&P500.

Birchcliff Energy Ltd., an intermediate gas and oil company, explores for, develops, and produces oil and natural gas, light oil, and natural gas liquids in Western Canada. The company has market cap of $1.27 billion. The firm principally holds interests in the Peace River Arch area of Alberta, which produces natural gas and oil in the Western Canadian Sedimentary Basin. It currently has negative earnings. As of December 31, 2016, it had proved plus probable reserves of 880.5 MMboe; 572.7 MMboe of proved reserves; and working interests in various gas plants, oil batteries, compressors, facilities, and infrastructure, as well as held 421,111 net acres of undeveloped land.

More notable recent Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news were published by: Globenewswire.com which released: “Tonix Pharmaceuticals to Present at the 2018 BIO International Convention” on May 30, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on June 06, 2018, Nasdaq.com published: “Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from ..” on May 31, 2018. More interesting news about Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were released by: Benzinga.com and their article: “40 Biggest Movers From Friday” published on June 18, 2018 as well as Streetinsider.com‘s news article titled: “B.Riley/FBR Starts Tonix Pharma (TNXP) at Buy” with publication date: June 06, 2018.

Among 4 analysts covering Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tonix Pharmaceuticals Holding Corp. has $18 highest and $6.0 lowest target. $10.50’s average target is 128.76% above currents $4.59 stock price. Tonix Pharmaceuticals Holding Corp. had 7 analyst reports since August 20, 2015 according to SRatingsIntel. Cantor Fitzgerald upgraded Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) on Thursday, June 2 to “Buy” rating. Oppenheimer maintained the shares of TNXP in report on Thursday, August 20 with “Outperform” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, November 4. The rating was maintained by Roth Capital with “Buy” on Thursday, November 9. Roth Capital upgraded the shares of TNXP in report on Friday, August 18 to “Buy” rating. The firm has “Buy” rating given on Monday, June 26 by Aegis Capital.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $38.84 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

Analysts await Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report earnings on August, 13. They expect $-0.73 EPS, down 12.31% or $0.08 from last year’s $-0.65 per share. After $-0.88 actual EPS reported by Tonix Pharmaceuticals Holding Corp. for the previous quarter, Wall Street now forecasts -17.05% EPS growth.

The stock decreased 0.43% or $0.02 during the last trading session, reaching $4.59. About 97,943 shares traded. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 28.97% since June 27, 2017 and is downtrending. It has underperformed by 41.54% the S&P500. Some Historical TNXP News: 24/05/2018 – TONIX PHARMACEUTICALS HOLDING – PRELIMINARY AND UNAUDITED ADVERSE EVENT (AES) DATA FROM PK STUDY WERE GENERALLY AS EXPECTED; 03/04/2018 – TONIX PHARMACEUTICALS HOLDING CORP – CO IS READY TO FILE NDA FOR TONMYA FOR TREATMENT OF PTSD IN 2019 IN EVENT OF A PERSUASIVE OUTCOME OF HONOR STUDY; 03/04/2018 – TNXP SEES TOPLINE DATA FOR TONMYA PHASE 3 IN 4Q 2018; 21/03/2018 – Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL; 14/05/2018 – Tonix Pharmaceuticals 1Q Loss/Shr 88c; 03/04/2018 – TONIX PHARMACEUTICALS – EVIDENCE FROM PHASE 2 STUDY OF TONMYA SHOWED POTENTIAL IMPROVEMENT OVER EXISTING THERAPIES USED TO TREAT MILITARY-RELATED PTSD; 11/05/2018 – TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88; 03/04/2018 – Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cycloben; 03/04/2018 – Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for the Treatment of PTSD; 01/05/2018 – TONIX GETS IND CLEARANCE BY FDA FOR TNX-102 SL